A prodrug form of moexiprilat
Related Products
Active Metabolite(s)
38047Moexiprilat
Labeled Version(s)
33814Moexipril-d5
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Moexipril (hydrochloride)

Item No. 21255

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3S-isoquinolinecarboxylic acid, monohydrochloride
CAS Number
82586-52-5
Synonyms
  • CI-925
  • RS 10085-197
  • SPM 925
Molecular Formula
C27H34N2O7 • HCl
Formula Weight
535.0
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 30 mg/mlEthanol: 25 mg/mlPBS (pH 7.2): 0.33 mg/ml
SMILES
COC1=C(OC)C=C(CN(C([C@H](C)N[C@H](C(OCC)=O)CCC2=CC=CC=C2)=O)[C@H](C(O)=O)C3)C3=C1.Cl
InChi Code
InChI=1S/C27H34N2O7.ClH/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32;/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32);1H/t17-,21-,22-;/m0./s1
InChi Key
JXRAXHBVZQZSIC-JKVLGAQCSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $49

    Add

    25 mg

    $96

    Add

    50 mg

    $143

    Add

    100 mg

    $259

    Add
    Product Description

    Moexipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor moexiprilat.1 It is converted to moexiprilat in vivo by side chain ester hydrolysis.2 Moexipril inhibits ACE in a cell-free assay (IC50 = 2.7 µM for the rabbit enzyme).1 It also inhibits phosphodiesterase 4 (IC50s = 38, 160, and 230 µM for PDE4B2, PDE4A5, and PDE4D5, respectively).2 Moexipril (0.1-30 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.1 It also reduces infarct volume in a rat model of focal cerebral ischemia when used at a concentration of 0.01 mg/kg.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Edling, O., Bao, G., Feelisch, M., et al. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalapril. J. Pharmacol. Exp. Ther. 275(2), 854-863 (1995).

    2. Cameron, R.T., Coleman, R.G., Day, J.P., et al. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochem. Pharmacol. 85(9), 1297-1305 (2013).

    3. Ravati, A., Junker, V., Kouklei, M., et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur. J. Pharmacol. 373(1), 21-33 (1999).